Aerobic Exercise May Ease Depression and Sleepiness in Parkinson’s Disease

As of April 2026, emerging evidence continues to refine the role of non-pharmacological interventions in managing Parkinson’s disease (PD), with aerobic exercise demonstrating consistent, though nuanced, benefits for motor and non-motor symptoms. While disease-modifying therapies remain elusive, lifestyle strategies are increasingly recognized as vital components of comprehensive care, particularly in addressing the progressive decline in mobility and alertness that significantly impacts quality of life for the over 10 million individuals living with PD worldwide.

Key Clinical Takeaways:

• Regular aerobic exercise is associated with measurable improvements in gait speed, balance, and daytime alertness in individuals with mild to moderate Parkinson’s disease.
• Benefits appear most pronounced when exercise is performed at moderate intensity for 30–45 minutes, three times weekly, over a minimum of 12 weeks.
• While cognitive and mood improvements are documented, effects on sleep architecture and long-term disease progression remain inconsistent across studies.

The pathophysiological burden of Parkinson’s extends beyond dopaminergic neuron loss in the substantia nigra, encompassing widespread neuroinflammation, oxidative stress, and disrupted cortical-basal ganglia circuitry. These mechanisms contribute not only to classic motor symptoms like bradykinesia and rigidity but also to non-motor manifestations including fatigue, executive dysfunction, and excessive daytime somnolence—collectively termed “cognitive fog” in clinical discourse. Current standard of care relies heavily on levodopa replacement and deep brain stimulation for refractory cases, yet both approaches address symptoms rather than underlying neurodegeneration, leaving a significant therapeutic gap that non-pharmacological modalities aim to fill.

Building on prior observational data, a 2024 multicenter randomized controlled trial published in Neurology investigated the effects of structured aerobic training on 180 participants with Hoehn and Yahr stages II–III PD over a 24-week period. Funded by the National Institute of Neurological Disorders and Stroke (NINDS) under NIH grant R01NS112358, the study assigned participants to either a treadmill-based aerobic intervention (70–80% heart rate reserve) or a stretching and flexibility control group. Primary outcomes assessed via the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part III revealed a mean 2.8-point improvement in motor scores favoring the exercise group (p=0.01), with secondary analyses showing enhanced performance on the Timed Up and Go test and reduced scores on the Epworth Sleepiness Scale.

Mechanistically, aerobic exercise may exert neuroprotective effects through upregulation of brain-derived neurotrophic factor (BDNF), modulation of microglial activation, and improved mitochondrial resilience in vulnerable neuronal populations. Functional MRI substudies from the same trial indicated increased prefrontal cortex activation during working memory tasks, suggesting a potential pathway for improved alertness and attentional control. As noted by Dr. Ayesha Khan, lead neurologist at the Cleveland Clinic’s Center for Neurological Restoration, “We’re seeing that sustained aerobic activity doesn’t just alleviate symptoms—it appears to engage endogenous repair mechanisms that support cortical efficiency, which may explain the observed gains in daytime vigilance even when motor gains plateau.”

“Exercise is not a replacement for medication, but it is a powerful modulator of network dysfunction in Parkinson’s. When prescribed with precision, it functions akin to a disease-modifying adjuvant.”

Importantly, the study’s limitations include a predominantly Caucasian cohort (78%) and reliance on self-reported exercise adherence via wearable monitors, which may overestimate actual compliance. While mood and alertness improved, no significant changes were observed in global cognition as measured by the MoCA, nor in REM sleep behavior disorder prevalence—highlighting the domain-specific nature of exercise’s impact. These findings align with a 2022 meta-analysis in JAMA Neurology that concluded aerobic exercise demonstrates moderate effect sizes for motor function (g=0.45) and fatigue (g=0.38) but minimal influence on cognitive decline or sleep microstructure in PD.

To translate these findings into clinical practice, neurologists and movement disorder specialists are increasingly integrating exercise prescription into routine visits, treating it with the same rigor as pharmacologic therapy. Patients seeking structured, supervised programs benefit from referral to certified physical therapists with expertise in neurorehabilitation, particularly those trained in evidence-based models like the Parkinson’s Foundation’s Exercise Framework. For individuals in the Latest York metropolitan area, accessing vetted board-certified neurologists with movement disorder specialization ensures appropriate screening for contraindications such as severe orthostatic hypotension or uncontrolled dyskinesia prior to initiating intense regimens.

Beyond individual care, community-based implementation presents both opportunity, and challenge. Safeguarding adherence requires removing barriers to access—cost, transportation, and perceived complexity—especially in underserved populations where PD prevalence is rising but resources remain scarce. Federally qualified health centers and Medicare Advantage plans are beginning to cover exercise physiology services under chronic care management codes, a shift supported by value-based care advocates. As emphasized by Dr. Luis Moreno, health services researcher at Johns Hopkins Bloomberg School of Public Health, “The real innovation isn’t in proving exercise helps—it’s in building systems that deliver it equitably and sustainably, treating it not as wellness advice but as covered, reimbursable care.”

“We must shift from asking ‘Should patients exercise?’ to ‘How do we ensure every patient with Parkinson’s has access to the right kind of exercise, at the right dose, with the right support?’”

Looking ahead, ongoing Phase III trials are examining whether combining aerobic exercise with cognitive training or pharmacological agents like istradefylline yields synergistic effects on cortical networks. The NIH-funded EXERT-PD trial (NCT04726143), slated for completion in late 2026, aims to determine if high-intensity interval training slows dopaminergic decline as measured by DaT-SPECT imaging—a potential landmark in establishing exercise as a true disease-modifying intervention. Until such data emerge, clinicians are advised to frame exercise not as alternative therapy but as foundational care, integral to maximizing functional independence and delaying caregiver burden.

For healthcare administrators and rehabilitation directors aiming to implement standardized exercise protocols within outpatient neurology clinics, partnering with certified neurologic physical therapists ensures adherence to safety guidelines and individualized progression. Similarly, organizations navigating reimbursement pathways or liability concerns related to supervised exercise programs may benefit from consulting healthcare compliance attorneys familiar with CMS regulations and state-specific scope-of-practice laws governing allied health services.

In the evolving landscape of Parkinson’s management, where precision medicine strives to match biomarkers with therapeutics, aerobic exercise stands out as a low-risk, high-reward intervention with demonstrable impact on daily function and well-being. Its value lies not in replacing established treatments but in amplifying their effects through systemic physiological adaptation—offering patients a tangible means of reclaiming agency in their care journey.

*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*